SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.
Identifieur interne : 004928 ( Main/Merge ); précédent : 004927; suivant : 004929SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.
Auteurs : Patrick C Y. Woo [Hong Kong] ; Susanna K P. Lau ; Hoi-Wah Tsoi ; Zhi-Wei Chen ; Beatrice H L. Wong ; Linqi Zhang ; Jim K H. Chan ; Lei-Po Wong ; Wei He ; Chi Ma ; Kwok-Hung Chan ; David D. Ho ; Kwok-Yung YuenSource :
- Vaccine [ 0264-410X ] ; 2005.
Descripteurs français
- KwdFr :
- Administration par voie orale, Animaux, Anticorps antiviraux (immunologie), Anticorps antiviraux (sang), Calendrier vaccinal, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (administration et posologie), Glycoprotéines membranaires (génétique), Glycoprotéines membranaires (immunologie), Immunoglobuline G (sang), Injections musculaires, Injections péritoneales, Interféron gamma (analyse), Interleukine-4 (analyse), Modèles animaux, Mâle, Protéines Escherichia coli, Protéines de l'enveloppe virale (administration et posologie), Protéines de l'enveloppe virale (génétique), Protéines de l'enveloppe virale (immunologie), Rappel de vaccin, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (), Tests de neutralisation, Vaccins antibactériens (administration et posologie), Vaccins antibactériens (immunologie), Vaccins synthétiques (administration et posologie), Vaccins synthétiques (immunologie), Vaccins à ADN (administration et posologie), Vaccins à ADN (immunologie), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Glycoprotéines membranaires, Protéines de l'enveloppe virale, Vaccins antibactériens, Vaccins synthétiques, Vaccins à ADN.
- analyse : Interféron gamma, Interleukine-4.
- génétique : Glycoprotéines membranaires, Protéines de l'enveloppe virale.
- immunologie : Anticorps antiviraux, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Vaccins antibactériens, Vaccins synthétiques, Vaccins à ADN, Virus du SRAS.
- sang : Anticorps antiviraux, Immunoglobuline G.
- Administration par voie orale, Animaux, Calendrier vaccinal, Glycoprotéine de spicule des coronavirus, Injections musculaires, Injections péritoneales, Modèles animaux, Mâle, Protéines Escherichia coli, Rappel de vaccin, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère, Tests de neutralisation.
English descriptors
- KwdEn :
- Administration, Oral, Animals, Antibodies, Viral (blood), Antibodies, Viral (immunology), Bacterial Vaccines (administration & dosage), Bacterial Vaccines (immunology), Escherichia coli Proteins, Immunization Schedule, Immunization, Secondary, Immunoglobulin G (blood), Injections, Intramuscular, Injections, Intraperitoneal, Interferon-gamma (analysis), Interleukin-4 (analysis), Male, Membrane Glycoproteins (administration & dosage), Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Mice, Mice, Inbred BALB C, Models, Animal, Neutralization Tests, SARS Virus (immunology), Severe Acute Respiratory Syndrome (prevention & control), Spike Glycoprotein, Coronavirus, Vaccines, DNA (administration & dosage), Vaccines, DNA (immunology), Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (immunology), Viral Envelope Proteins (administration & dosage), Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology).
- MESH :
- chemical , administration & dosage : Bacterial Vaccines, Membrane Glycoproteins, Vaccines, DNA, Vaccines, Synthetic, Viral Envelope Proteins.
- chemical , analysis : Interferon-gamma, Interleukin-4.
- chemical , blood : Antibodies, Viral, Immunoglobulin G.
- chemical , genetics : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , immunology : Antibodies, Viral, Bacterial Vaccines, Membrane Glycoproteins, Vaccines, DNA, Vaccines, Synthetic, Viral Envelope Proteins.
- immunology : SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- Administration, Oral, Animals, Escherichia coli Proteins, Immunization Schedule, Immunization, Secondary, Injections, Intramuscular, Injections, Intraperitoneal, Male, Mice, Mice, Inbred BALB C, Models, Animal, Neutralization Tests, Spike Glycoprotein, Coronavirus.
Abstract
Different forms of SARS coronavirus (SARS-CoV) spike protein-based vaccines for generation of neutralizing antibody response against SARS-CoV were compared using a mouse model. High IgG levels were detected in mice immunized with intraperitoneal (i.p.) recombinant spike polypeptide generated by Escherichia coli (S-peptide), mice primed with intramuscular (i.m.) tPA-optimize800 DNA vaccine (tPA-S-DNA) and boosted with i.p. S-peptide, mice primed with i.m. CTLA4HingeSARS800 DNA vaccine (CTLA4-S-DNA) and boosted with i.p. S-peptide, mice primed with oral live-attenuated Salmonella typhimurium (Salmonella-S-DNA-control) and boosted with i.p. S-peptide, mice primed with oral live-attenuated S. typhimurium that contained tPA-optimize800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide, and mice primed with oral live-attenuated S. typhimurium that contained CTLA4HingeSARS800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide. No statistical significant difference was observed among the Th1/Th2 index among these six groups of mice with high IgG levels. Sera of all six mice immunized with i.p. S-peptide, i.m. DNA vaccine control and oral Salmonella-S-DNA-control showed no neutralizing antibody against SARS-CoV. Sera of the mice immunized with i.m. tPA-S-DNA, i.m. CTLA4-S-DNA, oral Salmonella-S-DNA-control boosted with i.p. S-peptide, oral Salmonella-tPA-S-DNA, oral Salmonella-tPA-S-DNA boosted with i.p S-peptide, oral Salmonella-CTLA4-S-DNA and oral Salmonella-CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of <1:20-1:160. Sera of all the mice immunized with i.m. tPA-S-DNA boosted with i.p. S-peptide and i.m. CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of >or=1:1280. The present observation may have major practical value, such as immunization of civet cats, since production of recombinant proteins from E. coli is far less expensive than production of recombinant proteins using eukaryotic systems.
DOI: 10.1016/j.vaccine.2005.05.023
PubMed: 15993989
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002659
- to stream PubMed, to step Curation: 002659
- to stream PubMed, to step Checkpoint: 002524
- to stream Ncbi, to step Merge: 001038
- to stream Ncbi, to step Curation: 001038
- to stream Ncbi, to step Checkpoint: 001038
Links to Exploration step
pubmed:15993989Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.</title><author><name sortKey="Woo, Patrick C Y" sort="Woo, Patrick C Y" uniqKey="Woo P" first="Patrick C Y" last="Woo">Patrick C Y. Woo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, The University of Hong Kong, Room 423, University Pathology Building, Queen Mary Hospital, Hong Kong.</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Department of Microbiology, The University of Hong Kong, Room 423, University Pathology Building, Queen Mary Hospital</wicri:regionArea><wicri:noRegion>Queen Mary Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Lau, Susanna K P" sort="Lau, Susanna K P" uniqKey="Lau S" first="Susanna K P" last="Lau">Susanna K P. Lau</name></author><author><name sortKey="Tsoi, Hoi Wah" sort="Tsoi, Hoi Wah" uniqKey="Tsoi H" first="Hoi-Wah" last="Tsoi">Hoi-Wah Tsoi</name></author><author><name sortKey="Chen, Zhi Wei" sort="Chen, Zhi Wei" uniqKey="Chen Z" first="Zhi-Wei" last="Chen">Zhi-Wei Chen</name></author><author><name sortKey="Wong, Beatrice H L" sort="Wong, Beatrice H L" uniqKey="Wong B" first="Beatrice H L" last="Wong">Beatrice H L. Wong</name></author><author><name sortKey="Zhang, Linqi" sort="Zhang, Linqi" uniqKey="Zhang L" first="Linqi" last="Zhang">Linqi Zhang</name></author><author><name sortKey="Chan, Jim K H" sort="Chan, Jim K H" uniqKey="Chan J" first="Jim K H" last="Chan">Jim K H. Chan</name></author><author><name sortKey="Wong, Lei Po" sort="Wong, Lei Po" uniqKey="Wong L" first="Lei-Po" last="Wong">Lei-Po Wong</name></author><author><name sortKey="He, Wei" sort="He, Wei" uniqKey="He W" first="Wei" last="He">Wei He</name></author><author><name sortKey="Ma, Chi" sort="Ma, Chi" uniqKey="Ma C" first="Chi" last="Ma">Chi Ma</name></author><author><name sortKey="Chan, Kwok Hung" sort="Chan, Kwok Hung" uniqKey="Chan K" first="Kwok-Hung" last="Chan">Kwok-Hung Chan</name></author><author><name sortKey="Ho, David D" sort="Ho, David D" uniqKey="Ho D" first="David D" last="Ho">David D. Ho</name></author><author><name sortKey="Yuen, Kwok Yung" sort="Yuen, Kwok Yung" uniqKey="Yuen K" first="Kwok-Yung" last="Yuen">Kwok-Yung Yuen</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15993989</idno><idno type="pmid">15993989</idno><idno type="doi">10.1016/j.vaccine.2005.05.023</idno><idno type="wicri:Area/PubMed/Corpus">002659</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002659</idno><idno type="wicri:Area/PubMed/Curation">002659</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002659</idno><idno type="wicri:Area/PubMed/Checkpoint">002524</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002524</idno><idno type="wicri:Area/Ncbi/Merge">001038</idno><idno type="wicri:Area/Ncbi/Curation">001038</idno><idno type="wicri:Area/Ncbi/Checkpoint">001038</idno><idno type="wicri:doubleKey">0264-410X:2005:Woo P:sars:coronavirus:spike</idno><idno type="wicri:Area/Main/Merge">004928</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.</title><author><name sortKey="Woo, Patrick C Y" sort="Woo, Patrick C Y" uniqKey="Woo P" first="Patrick C Y" last="Woo">Patrick C Y. Woo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, The University of Hong Kong, Room 423, University Pathology Building, Queen Mary Hospital, Hong Kong.</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Department of Microbiology, The University of Hong Kong, Room 423, University Pathology Building, Queen Mary Hospital</wicri:regionArea><wicri:noRegion>Queen Mary Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Lau, Susanna K P" sort="Lau, Susanna K P" uniqKey="Lau S" first="Susanna K P" last="Lau">Susanna K P. Lau</name></author><author><name sortKey="Tsoi, Hoi Wah" sort="Tsoi, Hoi Wah" uniqKey="Tsoi H" first="Hoi-Wah" last="Tsoi">Hoi-Wah Tsoi</name></author><author><name sortKey="Chen, Zhi Wei" sort="Chen, Zhi Wei" uniqKey="Chen Z" first="Zhi-Wei" last="Chen">Zhi-Wei Chen</name></author><author><name sortKey="Wong, Beatrice H L" sort="Wong, Beatrice H L" uniqKey="Wong B" first="Beatrice H L" last="Wong">Beatrice H L. Wong</name></author><author><name sortKey="Zhang, Linqi" sort="Zhang, Linqi" uniqKey="Zhang L" first="Linqi" last="Zhang">Linqi Zhang</name></author><author><name sortKey="Chan, Jim K H" sort="Chan, Jim K H" uniqKey="Chan J" first="Jim K H" last="Chan">Jim K H. Chan</name></author><author><name sortKey="Wong, Lei Po" sort="Wong, Lei Po" uniqKey="Wong L" first="Lei-Po" last="Wong">Lei-Po Wong</name></author><author><name sortKey="He, Wei" sort="He, Wei" uniqKey="He W" first="Wei" last="He">Wei He</name></author><author><name sortKey="Ma, Chi" sort="Ma, Chi" uniqKey="Ma C" first="Chi" last="Ma">Chi Ma</name></author><author><name sortKey="Chan, Kwok Hung" sort="Chan, Kwok Hung" uniqKey="Chan K" first="Kwok-Hung" last="Chan">Kwok-Hung Chan</name></author><author><name sortKey="Ho, David D" sort="Ho, David D" uniqKey="Ho D" first="David D" last="Ho">David D. Ho</name></author><author><name sortKey="Yuen, Kwok Yung" sort="Yuen, Kwok Yung" uniqKey="Yuen K" first="Kwok-Yung" last="Yuen">Kwok-Yung Yuen</name></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Animals</term><term>Antibodies, Viral (blood)</term><term>Antibodies, Viral (immunology)</term><term>Bacterial Vaccines (administration & dosage)</term><term>Bacterial Vaccines (immunology)</term><term>Escherichia coli Proteins</term><term>Immunization Schedule</term><term>Immunization, Secondary</term><term>Immunoglobulin G (blood)</term><term>Injections, Intramuscular</term><term>Injections, Intraperitoneal</term><term>Interferon-gamma (analysis)</term><term>Interleukin-4 (analysis)</term><term>Male</term><term>Membrane Glycoproteins (administration & dosage)</term><term>Membrane Glycoproteins (genetics)</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Models, Animal</term><term>Neutralization Tests</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccines, DNA (administration & dosage)</term><term>Vaccines, DNA (immunology)</term><term>Vaccines, Synthetic (administration & dosage)</term><term>Vaccines, Synthetic (immunology)</term><term>Viral Envelope Proteins (administration & dosage)</term><term>Viral Envelope Proteins (genetics)</term><term>Viral Envelope Proteins (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie orale</term><term>Animaux</term><term>Anticorps antiviraux (immunologie)</term><term>Anticorps antiviraux (sang)</term><term>Calendrier vaccinal</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (administration et posologie)</term><term>Glycoprotéines membranaires (génétique)</term><term>Glycoprotéines membranaires (immunologie)</term><term>Immunoglobuline G (sang)</term><term>Injections musculaires</term><term>Injections péritoneales</term><term>Interféron gamma (analyse)</term><term>Interleukine-4 (analyse)</term><term>Modèles animaux</term><term>Mâle</term><term>Protéines Escherichia coli</term><term>Protéines de l'enveloppe virale (administration et posologie)</term><term>Protéines de l'enveloppe virale (génétique)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Rappel de vaccin</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère ()</term><term>Tests de neutralisation</term><term>Vaccins antibactériens (administration et posologie)</term><term>Vaccins antibactériens (immunologie)</term><term>Vaccins synthétiques (administration et posologie)</term><term>Vaccins synthétiques (immunologie)</term><term>Vaccins à ADN (administration et posologie)</term><term>Vaccins à ADN (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bacterial Vaccines</term><term>Membrane Glycoproteins</term><term>Vaccines, DNA</term><term>Vaccines, Synthetic</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Interferon-gamma</term><term>Interleukin-4</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Bacterial Vaccines</term><term>Membrane Glycoproteins</term><term>Vaccines, DNA</term><term>Vaccines, Synthetic</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Vaccins antibactériens</term><term>Vaccins synthétiques</term><term>Vaccins à ADN</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Interféron gamma</term><term>Interleukine-4</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Vaccins antibactériens</term><term>Vaccins synthétiques</term><term>Vaccins à ADN</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Immunoglobuline G</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Animals</term><term>Escherichia coli Proteins</term><term>Immunization Schedule</term><term>Immunization, Secondary</term><term>Injections, Intramuscular</term><term>Injections, Intraperitoneal</term><term>Male</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Models, Animal</term><term>Neutralization Tests</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie orale</term><term>Animaux</term><term>Calendrier vaccinal</term><term>Glycoprotéine de spicule des coronavirus</term><term>Injections musculaires</term><term>Injections péritoneales</term><term>Modèles animaux</term><term>Mâle</term><term>Protéines Escherichia coli</term><term>Rappel de vaccin</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère</term><term>Tests de neutralisation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Different forms of SARS coronavirus (SARS-CoV) spike protein-based vaccines for generation of neutralizing antibody response against SARS-CoV were compared using a mouse model. High IgG levels were detected in mice immunized with intraperitoneal (i.p.) recombinant spike polypeptide generated by Escherichia coli (S-peptide), mice primed with intramuscular (i.m.) tPA-optimize800 DNA vaccine (tPA-S-DNA) and boosted with i.p. S-peptide, mice primed with i.m. CTLA4HingeSARS800 DNA vaccine (CTLA4-S-DNA) and boosted with i.p. S-peptide, mice primed with oral live-attenuated Salmonella typhimurium (Salmonella-S-DNA-control) and boosted with i.p. S-peptide, mice primed with oral live-attenuated S. typhimurium that contained tPA-optimize800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide, and mice primed with oral live-attenuated S. typhimurium that contained CTLA4HingeSARS800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide. No statistical significant difference was observed among the Th1/Th2 index among these six groups of mice with high IgG levels. Sera of all six mice immunized with i.p. S-peptide, i.m. DNA vaccine control and oral Salmonella-S-DNA-control showed no neutralizing antibody against SARS-CoV. Sera of the mice immunized with i.m. tPA-S-DNA, i.m. CTLA4-S-DNA, oral Salmonella-S-DNA-control boosted with i.p. S-peptide, oral Salmonella-tPA-S-DNA, oral Salmonella-tPA-S-DNA boosted with i.p S-peptide, oral Salmonella-CTLA4-S-DNA and oral Salmonella-CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of <1:20-1:160. Sera of all the mice immunized with i.m. tPA-S-DNA boosted with i.p. S-peptide and i.m. CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of >or=1:1280. The present observation may have major practical value, such as immunization of civet cats, since production of recombinant proteins from E. coli is far less expensive than production of recombinant proteins using eukaryotic systems.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004928 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004928 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:15993989
|texte= SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:15993989" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |